New drug may help lung transplant patients fight rejection
NCT ID NCT06990711
First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 22 times
Summary
This early-stage trial tests a drug called siltuximab for lung transplant patients experiencing antibody-mediated rejection, a serious condition where the immune system attacks the new lung. The study involves 30 adults who are already receiving standard rejection treatment. The main goal is to see if adding siltuximab is safe and tolerable, with future studies needed to check if it works better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBODY MEDIATED REJECTION OF LUNG TRANSPLANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Utah
RECRUITINGSaint Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Washington University School, of Medicine, Barnes-Jewish Hospital
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.